Trust Co. of Oklahoma Buys 177 Shares of Novartis AG (NYSE:NVS)

Trust Co. of Oklahoma lifted its position in Novartis AG (NYSE:NVS) by 1.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,898 shares of the company’s stock after purchasing an additional 177 shares during the quarter. Trust Co. of Oklahoma’s holdings in Novartis were worth $1,158,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in NVS. Bank of Montreal Can grew its stake in Novartis by 343.5% during the second quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock worth $70,652,000 after buying an additional 509,567 shares during the last quarter. World Investment Advisors LLC bought a new stake in Novartis during the 3rd quarter worth approximately $30,063,000. Fisher Asset Management LLC increased its holdings in Novartis by 15.7% during the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after purchasing an additional 231,851 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in Novartis in the 3rd quarter valued at $24,096,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Novartis in the third quarter worth $21,078,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

NVS has been the subject of a number of research reports. BMO Capital Markets raised their target price on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus target price of $121.50.

Novartis Stock Down 1.6 %

Shares of NYSE:NVS opened at $98.17 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The stock has a market cap of $200.65 billion, a price-to-earnings ratio of 11.40, a P/E/G ratio of 1.44 and a beta of 0.57. The company has a 50 day moving average of $100.22 and a 200-day moving average of $108.81. Novartis AG has a one year low of $92.35 and a one year high of $120.92.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter in the previous year, the business earned $1.74 EPS. On average, sell-side analysts forecast that Novartis AG will post 7.62 earnings per share for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.